

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 1416 10 US01

OGLE et al.

Confirmation No.

No.: 3022

Application No.:

10/008,430

Examiner: Unknown

Filed:

November 13, 2001

Group Art Whit: 376

3763

For:

MEDICAL DEVICES THAT STIMULATE GROWTH FACTOR PRODUCTION

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This information is being filed before the mailing date of a first Office Action on the merits. No certification or fee is required.

Respectfully submitted,

Peter S. Dardi, Ph.D.

Registration No. 39,650

Customer No. 24113
Patterson, Thuente, Skaar & Christensen, P.A. 4800 IDS Center
80 South 8th Street
Minneapolis, Minnesota 55402-2100

Telephone: (612) 349-5746

Please grant any extension of time necessary for entry; charge any fee due to Deposit Account No. 16-0631.

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on



FORM PROPERTY MODIFIED

Docket No.: 1416.10US01 Application No.: 10/008,430

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

APPLICANT: OGLE et al.

FILING DATE: November 13, 2001

GROUP ART UNIT: 3763

EXAMINER	DOCUMENT	1	<u> </u>			FILING DATE IF
INITIAL	NO.	DATE	NAME	CLASS	SUBCLASS	APPROPRIATE
	4,648,881	03/1987	Carpentier et al.			
	4,786,287	11/1988	Nashef et al.			
	4,798,611	01/1989	Freeman, Jr.			
	4,828,563	05/1989	Muller-Lierheim			
	4,883,755	11/1989	Carabasi et al.			
	5,002,582	03/1991	Guire et al.			
	5,147,400	09/1992	Kuplan et al.			
	5,147,514	09/1992	Mechanic			
	5,192,312	03/1993	Orton			
	5,194,596	03/1993	Tischer et al.			
	5,263,992	11/1993	Guire			
	5,308,641	05/1994	Cahalan et al.			
	5,386,012	01/1995	Strid			l
	5,607,918	03/1997	Eriksson et al.			
	5,613,982	03/1997	Goldstein			
	5,631,011	05/1997	Wadstrom			
	6,033,719	03/2000	Keogh			
	6,099,563	08/2000	Zhong			To
	6,113,947	09/2000	Cleland et al.			
	6,124,131	09/2000	Semenza			SEP 17 2
	6,218,179	04/2001	Webster et al.			7p
	6,245,966	06/2001	DeGregori			17 17
	6,375,680	04/2002	Carlyle			/ Y. 21 2. /
						ZIZZ ZIZZ L. ROL
						POLM POLM
					D 67	
					•	20
		 				S
		 				n m
				· <u> </u>		
		1			=	9
					1 - 8	200
					160	2002
EXAMINER SIGNATURE				DATEC	ONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



EXAMINER SIGNATURE

		1 450 3 01 3				
FORM PTO VANCOUS DIFIED	Docket No.: 1416.10US01	Application No.: 10/008,430				
INFORMATION DISCLOSURE CITATION	APPLICANT: OGLE et al.					
IN AN APPLICATION	FILING DATE: November 13,	2001				
	GROUP ART UNIT: 3763					
OTHER DOCUMENTS (including Au	thor, Title, Date, Pertiner	t Pages, etc.)				
Benjamin et al., "Conditional switching	of vascular endothelial gro	owth factor (VEGF)				
expression in tumors: Induction of endot	thelial cell shedding and re	egression of				
hemangioblastoma-like vessels by VEG (1997), pages 8761-8766						
Spyridopoulos et al., "Vascular Endothe	lial Growth Factor Inhibits	Endothelial Cell				
Apoptosis Induced by Tumor Necrosis F	factor-x: Balance Between	Growth and Death				
Signals," J. Mol. Cell. Cardiol., Vol. 29	(1997) pages 1321-1330	1 D 1'1'				
Senger et al., "Stimulation of Endothelia Factor/Vascular Endothelial Growth Fac	tor through Compretive N	lar Permeability				
$\alpha_{\rm v}\beta_3$ Integrin, Osteopontin and Thrombin	" American Journal of Pa	thology Vol. 140 No CD				
(1996) pages 293-305	i, minorioum sourman or re	miology, vol. 149. 100 12				
Weatherford et al., "Vascular endothelial	growth factor and heparin	n in a biologic glue				
promotes human aortic endothelial cell p	roliferation with aortic sm	ooth muscle cell				
inhibition," Surgery Vol. 120 (1996) pag	es 433-439					
Van Belle et al., "Stent Endothelializatio	n: Time Course, Impact of	Local Catheter				
(1996) pages 293-305 Weatherford et al., "Vascular endothelial promotes human aortic endothelial cell p inhibition," Surgery Vol. 120 (1996) pag Van Belle et al., "Stent Endothelializatio Delivery, Feasibility of Recombinant Pro Expedition," Circulation, Vol. 95 (1997)	otein Administration, and I	Response to Cytokine				
Asahara et al "Syneroistic Effect of Vas	pages 430-446	Factor and Rasia				
Fibroblast Growth Factor on Angiogenes	Asahara et al., "Synergistic Effect of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on Angiogenesis In Vivo," Circulation, Vol. 92 (1995) (Suppl II);					
II365-II371.		, , , , , , , , , , , , , , , , , , , ,				
Van Belle et al., "Passivation of Metallic	Stents After Arterial Gene	e Transfer of phVEGF ₁₆₅				
In hibits Thrombus Formation and Intima	al Thickening," JACC Vol	. 29, No. 6 (1997) pages				
1371-1379.	36 1 1 177 177 1					
Bengtsson et al., "Endothelialization of	Mechanical Heart Valves	In Vitro with Cultured				
Adult Human Cells," J. Heart Valve Dis Carmeliet et al., "Angiogenesis in cance	r and other diseases " Nat	oso, May 1993.				
257, September 14, 2000.	and office disouses, 14d	are, voi. 407, pp. 247-				
Dunkirk, "Photochemical Coatings for t	he Prevention of Bacteria	l Colonization," Journal				
of Biomaterials Applications, Vol. 6, pp	. 131-156, October 1991.	- 1				
Tsuzuki et al., "Vascular Endothelial Gr	owth Factor (VEGF) Mod	lulation by Targeting				
Hypoxia-inducible Factor-1α→Hypoxia	Response Element → VE	GF Cascade S				
Differentially Regulates Vascular Respo	nse and Growth Rate in T	umors," Cancer				
Research, 60, pp. 6248-6252, November	13, 2000.					
		11. F				
		<u> </u>				
		<u></u>				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

DATE CONSIDERED



FORM PTO TO MODIFIED

Docket No.: 1416.10US01 APPLICANT: OGLE et al. Application No.: 10/008,430

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

FILING DATE: November 13, 2001

GROUP ART UNIT: 3763

 				OUP ART UNIT:	3763			
		FOREIG	GN PATENT DO	CUMENTS				
EXAMINER INITIAL	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANS YES	LATION NO	
	WO 86/00526	01/1986	PCT					
	EP 0476983A	09/1992	Europe					
	EP 0506477A'	09/1992	Europe					
	EP 0550296A	07/1993	Europe					
	WO 95/24473	14-9-95	PCT				- T	
	EP 0742020A2	11/1996	Europe				7	
	WO 99/37337	09/1999	PCT				S A	
	WO 01/41825	06/2001	PCT					
						3 5		
						(009)	: <	
						200 200	3 In	
						8	U	
						0/200700	1 23	
						0.		
						117 2	R	
						11.	=	
						2032 ROOM	77	
						<u> </u>		
							,	
	OTHER DOCU	MENTS (in	cluding Author, T	itle, Date, Pe	rtinent Pages,	etc.)		
	Watanabe et al.,	"Vascular pe	rmeability factor/v	ascular endot	helial growth	factor		
	(VPF/VEGF) delays and induces escape from senescence in human dermal microvascular							
	endothelial cells,	"Oncogene	Vol. 14 (1997) pa	ges 2025-203	2			
	Van Belle et al.,	"Accelerated	Endothelialization	n by Local De	livery of Reco	mbinant F	Iuman	
i	Vascular Endoth	elial Growth	Factor Reduces In	-Stent Intima	l Formation,"	Biochem.		
			Vol. 235 (1997) p					
			rmeability Factor/					
	Anchorage-Disruption-Induced Apoptosis in Microvessel Endothelial Cells by Inducing							
	Scaffold Formati	on," Experin	nental Cell Researc	ch Vol. 233 (1	1997) pages 34	10-349		
EXAMINE	R SIGNATURE			DATE C	ONSIDERED	,		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.